Litigation Details for In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)

In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)

Docket	1:16-cv-07926	Date Filed	2016-10-11
Court	District Court, S.D. New York	Date Terminated
Cause	15:78m(a) Securities Exchange Act	Assigned To	James Paul Oetken
Jury Demand	Plaintiff	Referred To
Patents	7,449,012
Link to Docket	External link to docket

Details for In Re: MYLAN N v. SECURITIES LITIGATION (S.D.N.Y. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-10-11	39	Amended Complaint	expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …settling its patent infringement suit against Teva Pharmaceuticals (“Teva”) relating to the patents covering…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen,	External link to document
2016-10-11	45	Consolidated Amended Complaint	expiration of U.S. Patent Nos. 7,449,012 B2 (the “‘012 patent”) and 7,794,432 B2 (the “‘432 patent”), which expire…Numbers 7,449,012, 7,794,432, 8,048,035, and 8,870,827 (the “EpiPen Patents”). These four patents have a …settling its patent infringement suit against Teva Pharmaceuticals (“Teva”) relating to the patents covering…additional patents for features that were subsequently integrated into the EpiPen: U.S. Patent Numbers…The issuance of the EpiPen Patents, and Mylan’s designation of these patents as covering the EpiPen,	External link to document

In re Mylan N.V. Securities Litigation, 1:16-cv-07926: Litigation Summary and Analysis

Last updated: August 5, 2026

The case was a putative investor class action against Mylan N.V. and senior executives over alleged securities fraud tied to EpiPen pricing, Medicaid rebate classification, competition, and regulatory disclosures. The U.S. District Court for the Southern District of New York dismissed the amended complaint with prejudice on March 29, 2018. The court held that the plaintiffs had not adequately pleaded a material misstatement or omission, scienter, or loss causation under the federal securities laws. The case did not create patent, Orange Book, Paragraph IV, or biosimilar exposure for Mylan. Its principal risk was securities-law liability arising from the company’s EpiPen commercialization strategy and Medicaid reporting practices. [1]

What was In re Mylan N.V. Securities Litigation?

In re Mylan N.V. Securities Litigation was a consolidated putative class action brought by investors who purchased Mylan securities during a proposed class period associated with the company’s EpiPen pricing controversy. The action was filed in the Southern District of New York under docket number 1:16-cv-07926.

The defendants included:

• Mylan N.V.
• Mylan’s chief executive officer Heather Bresch
• Mylan’s executive chairman Robert J. Coury
• Other senior officers and directors named in the operative pleadings

The plaintiffs asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The central theory was that Mylan had misled investors about the commercial and regulatory basis for EpiPen’s profitability while concealing problems involving Medicaid rebate treatment and competitive threats.

The claims followed intense public and regulatory scrutiny of EpiPen pricing. Mylan had increased the product’s price substantially over several years, with a two-pack reaching approximately $600 in list price. Public criticism intensified in 2016, followed by congressional inquiries, regulatory attention, and a decline in Mylan’s share price.

What allegations did investors make against Mylan?

The amended complaint focused on four related disclosure theories.

EpiPen Medicaid classification

Plaintiffs alleged that Mylan improperly treated EpiPen as a generic product for purposes of the Medicaid Drug Rebate Program. Under the statutory rebate structure, branded drugs generally carry a higher rebate obligation than generic drugs. Plaintiffs alleged that Mylan’s classification reduced its Medicaid rebate payments and inflated reported profitability.

The complaint contended that Mylan knew or should have known the classification was problematic and failed to disclose the resulting regulatory and financial risk.

The district court rejected the theory as pleaded. The court concluded that the plaintiffs had not identified a sufficiently concrete false statement establishing that Mylan had affirmatively misrepresented the product’s legal classification or that the company had a duty to disclose every aspect of its Medicaid rebate position. [1]

EpiPen price increases

The plaintiffs alleged that Mylan’s public statements about EpiPen pricing and access were misleading because the company did not disclose the extent to which list-price increases drove revenue and margin growth.

The court treated several challenged statements as generalized corporate statements, opinions, or forward-looking disclosures rather than actionable factual representations. The complaint also did not sufficiently connect the challenged statements to a specific securities-law violation.

Competition and market protection

The complaint alleged that Mylan understated competitive threats, including the potential effect of alternative epinephrine delivery systems and authorized or generic competition.

Plaintiffs argued that Mylan’s statements gave investors an inaccurate view of EpiPen’s market position and pricing power. The court found that the allegations did not establish that the challenged statements were false when made or that the defendants possessed the required fraudulent intent.

Regulatory and governmental investigations

The complaint relied in part on later government scrutiny, including congressional inquiries and regulatory investigations, as evidence that earlier Mylan disclosures were misleading.

The court held that subsequent investigations or adverse publicity did not, by themselves, establish that prior statements were false. A later inquiry can support a securities claim only when the complaint connects it to a specific earlier misrepresentation and pleads facts showing that the defendants knew the statement was false or misleading when issued.

What claims did the court dismiss?

The court dismissed the federal securities claims under Section 10(b) and Rule 10b-5. It also dismissed the control-person claims under Section 20(a), which depended on an underlying primary securities violation.

Section 10(b) and Rule 10b-5

To plead a Section 10(b) claim, investors had to allege:

1. A material misrepresentation or omission;
2. Scienter;
3. A connection with the purchase or sale of securities;
4. Reliance;
5. Economic loss; and
6. Loss causation.

The Private Securities Litigation Reform Act imposed heightened pleading requirements, including a particularized showing of fraudulent intent. The court held that the complaint failed at multiple points.

Scienter

The court concluded that the complaint did not support a strong inference that Mylan’s executives acted with fraudulent intent. The allegations showed that management was involved in EpiPen pricing and regulatory matters, but participation in ordinary corporate decisions did not establish that executives knowingly deceived investors.

The court also declined to infer scienter merely from the size of EpiPen price increases, the importance of the product to Mylan, or the later public controversy.

Loss causation

The court found that the complaint did not adequately establish that a corrective disclosure revealed the alleged fraud and caused the claimed stock-price losses. General news coverage, political criticism, and regulatory attention were not enough without a clear connection between the disclosure and the alleged misrepresentation.

Section 20(a)

The Section 20(a) claims against individual defendants failed because the plaintiffs did not adequately plead a primary Section 10(b) violation. The control-person claims therefore fell with the underlying securities claims.

When was the Mylan securities case dismissed?

Judge Edgardo Ramos dismissed the amended complaint on March 29, 2018, in an opinion reported at 2018 WL 1597399. The dismissal was with prejudice, ending the district-court action on the merits rather than allowing another amended pleading. [1]

The dismissal substantially reduced Mylan’s exposure in the investor litigation. The decision also limited the use of the EpiPen Medicaid classification dispute as a securities-fraud theory absent a particularized showing that Mylan made a false statement, knew it was false, and caused investor losses through a corrective disclosure.

What was the court’s analysis of Mylan’s EpiPen disclosures?

The court’s analysis turned on the difference between corporate controversy and actionable securities fraud.

Mylan’s conduct could be criticized by investors, lawmakers, or regulators without necessarily constituting a Rule 10b-5 violation. Securities law requires a false or misleading statement connected to a material fact. It does not impose liability for every omission, aggressive business strategy, pricing decision, or regulatory dispute.

The court’s reasoning had four practical implications:

• A company does not automatically have to disclose every unfavorable regulatory interpretation.
• A later government investigation does not prove that earlier statements were fraudulent.
• Executive knowledge of a business issue does not alone establish scienter.
• A stock decline following public controversy does not establish loss causation unless the market learned the truth concealed by the challenged statement.

The opinion also reflected the limits of “fraud by hindsight.” Plaintiffs could not establish liability simply by showing that EpiPen pricing became politically controversial or that Mylan later faced regulatory and commercial pressure.

What was the litigation timeline?

Date	Event
2016	EpiPen pricing controversy escalated; Mylan faced public, congressional, and regulatory scrutiny
2016	Investor securities actions were filed in federal court
2016-2017	Actions were consolidated under No. 1:16-cv-07926
2017	Plaintiffs filed an amended consolidated complaint
March 29, 2018	District court dismissed the amended complaint with prejudice
After dismissal	The federal securities action no longer presented active district-court claims against Mylan based on the EpiPen allegations

The litigation timeline is separate from Mylan’s other EpiPen-related proceedings, including government investigations, consumer actions, antitrust litigation, and Medicaid-related matters. Those proceedings should not be treated as part of the securities case unless they are separately identified by docket number.

Did the case involve patent litigation or Paragraph IV challenges?

No. In re Mylan N.V. Securities Litigation was an investor-fraud case, not a Hatch-Waxman patent case.

The proceeding did not determine:

• Whether any EpiPen patent was valid or infringed;
• Whether a generic applicant made a Paragraph IV certification;
• Whether Mylan had Orange Book-listed patents;
• Whether Teva, Impax, or another competitor could launch a generic epinephrine auto-injector;
• Whether Mylan’s device, formulation, or manufacturing patents were enforceable.

EpiPen’s commercial protection involved a combination of patents, device know-how, regulatory positioning, manufacturing capability, brand recognition, and market access. Those issues were relevant to the commercial background but were not adjudicated in the securities case.

What was the FDA and Orange Book relevance?

The FDA and Medicaid issues were central to the factual background, but the case was not an FDA approval challenge.

EpiPen is an epinephrine auto-injector regulated as a drug-device combination product. Mylan’s market position depended on FDA approval, device reliability, manufacturing scale, pharmacy distribution, and reimbursement treatment.

The Medicaid rebate classification issue involved reimbursement economics rather than Orange Book patent listing. A dispute over whether a product should be treated as branded or generic for rebate purposes does not itself establish patent infringement or invalidate an FDA approval.

Mylan’s later commercialization strategy also included an authorized generic EpiPen, which affected pricing and competitive dynamics. That business decision did not convert the securities case into a patent or ANDA proceeding.

How strong was the investor case against Mylan?

The investor case was weak under the PSLRA pleading standard for three reasons.

The alleged misstatements were not sufficiently specific

The complaint challenged broad statements about pricing, access, competition, and regulatory compliance. The court required a clear identification of what was false, why it was false, and when the defendants knew it was false.

The scienter allegations relied heavily on inference

The plaintiffs relied on Mylan’s executive involvement, the financial significance of EpiPen, and the magnitude of the price increases. Those facts suggested motive or opportunity but did not create the required strong inference of fraudulent intent.

The corrective-disclosure theory was incomplete

The complaint did not adequately show that a particular disclosure corrected a prior false statement and caused the stock decline. Public controversy and government scrutiny were not interchangeable with a disclosure of previously concealed fraud.

Did Mylan settle the securities litigation?

The district court’s operative disposition was dismissal with prejudice, not a merits settlement. The dismissal eliminated the pleaded federal securities claims in the action identified by docket number 1:16-cv-07926.

Other Mylan litigation involving EpiPen pricing, Medicaid rebates, antitrust issues, consumer claims, or government investigations had separate legal theories and procedural histories. Settlement activity in those matters should not be attributed to this securities case without a specific docket or settlement order.

What was the commercial impact of the case?

The litigation created potential damages exposure for investors who purchased Mylan securities and alleged that the company’s disclosures inflated the market price. It did not directly threaten EpiPen sales, FDA approval, patent exclusivity, manufacturing rights, or generic entry.

The broader EpiPen controversy did create commercial pressure through:

• Lower public tolerance for price increases;
• Increased payer and pharmacy scrutiny;
• Entry by authorized and generic alternatives;
• Congressional and regulatory oversight;
• Brand and reputation damage;
• Margin pressure from rebates and discounts.

The securities dismissal reduced one category of financial risk. It did not resolve the underlying commercial or regulatory questions surrounding EpiPen pricing and Medicaid treatment.

Key Takeaways

• In re Mylan N.V. Securities Litigation was a federal investor class action, not a patent or Hatch-Waxman case.
• The claims arose from EpiPen pricing, Medicaid rebate classification, competitive threats, and alleged disclosure failures.
• The Southern District of New York dismissed the amended complaint with prejudice on March 29, 2018.
• The court found inadequate allegations of actionable misstatements, scienter, and loss causation.
• Section 20(a) control-person claims failed because the primary Section 10(b) claims failed.
• The case did not decide EpiPen patent validity, Orange Book status, Paragraph IV risk, biosimilar exposure, or generic launch rights.
• Separate EpiPen antitrust, consumer, Medicaid, regulatory, and patent proceedings must be analyzed independently.
• The decision limited securities damages exposure arising from the EpiPen pricing controversy but did not eliminate Mylan’s broader regulatory and commercial risks.

FAQs About In re Mylan N.V. Securities Litigation

What is the citation for the Mylan securities decision?

The principal district-court decision is In re Mylan N.V. Securities Litigation, 2018 WL 1597399 (S.D.N.Y. Mar. 29, 2018).

Who was the judge in the Mylan securities case?

The case was decided by Judge Edgardo Ramos of the U.S. District Court for the Southern District of New York.

Was the Mylan securities complaint dismissed with prejudice?

Yes. The amended complaint was dismissed with prejudice, ending the pleaded securities claims in the district court.

Did the court find that Mylan violated Medicaid rebate law?

No. The securities opinion did not establish a Medicaid rebate violation. It held that the plaintiffs had not adequately pleaded securities fraud based on the alleged EpiPen classification and related disclosures.

Did the Mylan case affect generic EpiPen entry?

No. The securities litigation did not adjudicate patents, FDA approval, ANDA certifications, or generic entry rights.

References

1. In re Mylan N.V. Securities Litigation, No. 1:16-cv-07926, 2018 WL 1597399 (S.D.N.Y. Mar. 29, 2018).

2. Mylan N.V. Mylan N.V. Annual Report on Form 10-K for the fiscal year ended December 31, 2016. U.S. Securities and Exchange Commission, 2017.

3. U.S. Securities and Exchange Commission. (2015). Commission guidance regarding management’s discussion and analysis of financial condition and results of operations. Release No. 33-8350.

4. Medicaid Drug Rebate Program, 42 U.S.C. § 1396r-8.